In Switzerland, the standard of care is a non-myeloablative chemotherapy regimen such as vinorelbine plus G-CSF or gemcitabine plus G-CSF providing low risk of fever in neutropenia, ambulatory cost-efficient management of the mobilization treatment and a reliable apheresis planning [11, 13, 15, 17]. Here, CSF3 is linked to Decreased total neutrophil count.